POXEL SA announced that Takashi Kaneko, MD, PhD, has joined the company as Senior Vice President Medical effective September 1, 2018, to lead the company's drug development and medical affairs activities as well as the team in Japan. In addition, the company has established a wholly-owned Japanese subsidiary in Tokyo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4645 EUR | -0.85% | -5.20% | -15.70% |
Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-15.70% | 24.61M | |
+20.44% | 125B | |
+22.05% | 114B | |
+25.30% | 26.73B | |
-23.30% | 19.43B | |
-18.10% | 16.22B | |
-18.89% | 15.33B | |
+10.66% | 14.42B | |
-48.41% | 14.33B | |
+56.24% | 14.2B |
- Stock Market
- Equities
- POXEL Stock
- News Poxel
- POXEL SA Appoints Takashi Kaneko as Senior Vice President Medical; Establishes Wholly-Owned Japanese Subsidiary in Tokyo